Figure 1.

In vivo efficacy with 27 as a single agent in WiDr tumor xenograft model: WiDr cells were implanted subcutaneously in the right flanks of female BALB/c nude mice. After tumors reached ∼100 mm³, mice were randomly assigned to three groups (n = 8 mice per group). Group 1 was administered with 50 mg/kg, oral gavage, bid; group 2 was treated with 10 mg/kg, ip, bid. Tumor volumes were recorded every 3–4 days. The study was carried out for 22 days. Mann–Whitney test was used to compute significance. *P ≤ 0.05.